Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which … Read more
Telix Pharmaceuticals Limited (TLX) - Total Assets
Latest total assets as of December 2025: $1.77 Billion USD
Based on the latest financial reports, Telix Pharmaceuticals Limited (TLX) holds total assets worth $1.77 Billion USD as of December 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Telix Pharmaceuticals Limited - Total Assets Trend (2000–2025)
This chart illustrates how Telix Pharmaceuticals Limited’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Telix Pharmaceuticals Limited - Asset Composition Analysis
Current Asset Composition (December 2025)
Telix Pharmaceuticals Limited's total assets of $1.77 Billion consist of 27.9% current assets and 72.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 12.0% |
| Accounts Receivable | $207.29 Million | 11.7% |
| Inventory | $55.55 Million | 3.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $590.00 Million | 33.3% |
| Goodwill | $298.10 Million | 16.8% |
Asset Composition Trend (2000–2025)
This chart illustrates how Telix Pharmaceuticals Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Telix Pharmaceuticals Limited's current assets represent 27.9% of total assets in 2025, a decrease from 32.5% in 2000.
- Cash Position: Cash and equivalents constituted 12.0% of total assets in 2025, down from 31.9% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 49.0% of total assets, an increase from 0.0% in 2000.
- Asset Diversification: The largest asset category is intangible assets at 33.3% of total assets.
Telix Pharmaceuticals Limited Competitors by Total Assets
Key competitors of Telix Pharmaceuticals Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx SE
OTCGREY:ARGNF
|
USA | $7.18 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $1.48 Billion |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
2cureX AB
ST:2CUREX
|
Sweden | Skr5.18 Million |
Telix Pharmaceuticals Limited - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Telix Pharmaceuticals Limited generates 0.68x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Telix Pharmaceuticals Limited is currently not profitable relative to its asset base.
Telix Pharmaceuticals Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.43 | 2.78 | 4.69 |
| Quick Ratio | 1.27 | 2.66 | 4.66 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $147.80 Million | $ 587.65 Million | $ 73.67 Million |
Telix Pharmaceuticals Limited - Advanced Valuation Insights
This section examines the relationship between Telix Pharmaceuticals Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.13 |
| Latest Market Cap to Assets Ratio | 1.43 |
| Asset Growth Rate (YoY) | 16.8% |
| Total Assets | $1.77 Billion |
| Market Capitalization | $2.53 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Telix Pharmaceuticals Limited's assets above their book value (1.43 x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Telix Pharmaceuticals Limited's assets grew by 16.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Telix Pharmaceuticals Limited (2000–2025)
The table below shows the annual total assets of Telix Pharmaceuticals Limited from 2000 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $1.77 Billion | +16.78% |
| 2024-12-31 | $1.52 Billion | +280.72% |
| 2023-12-31 | $398.30 Million | +52.85% |
| 2022-12-31 | $260.59 Million | +137.30% |
| 2021-12-31 | $109.81 Million | -30.42% |
| 2020-12-31 | $157.82 Million | +53.81% |
| 2019-12-31 | $102.61 Million | +33.76% |
| 2018-12-31 | $76.71 Million | +50.13% |
| 2017-12-31 | $51.09 Million | +174.50% |
| 2016-12-31 | $18.61 Million | +4.49% |
| 2015-12-31 | $17.81 Million | +0.45% |
| 2014-12-31 | $17.73 Million | -4.36% |
| 2013-12-31 | $18.54 Million | +57.46% |
| 2011-12-31 | $11.78 Million | +25.36% |
| 2000-12-31 | $9.39 Million | -- |